Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional)

Funder: National Institutes of Health

Due Date: 7/24/2020

Budget: Negotiable

Opportunity: PAR-18-494

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.

Leave a Reply